Materialise(US:MTLS)2026-02-19 11:05Revenue Performance - Total revenue for Q4 2025 increased by 6.8% to 70,164 kEUR from 65,680 kEUR in Q4 2024, driven by a 16.3% growth in the Materialise Medical segment[5][7] - Full year 2025 total revenue remained stable at 267,633 kEUR compared to 266,765 kEUR in 2024, with a 15.4% growth in the Materialise Medical segment[7][17] - Revenue for Q4 2025 reached $82.442 million, a 17.5% increase from $70.164 million in Q4 2024[34] - Total revenues for Q4 2025 amounted to €70,164,000, an increase of 6.3% from €65,680,000 in Q4 2024[44] - The Medical segment generated revenues of €37,016,000 in Q4 2025, up 16.8% from €31,837,000 in Q4 2024[44] - The Materialise Manufacturing segment reported a revenue decrease of 13.2% to 92,486 kEUR for 2025, impacted by macroeconomic headwinds[20] Profitability Metrics - Adjusted EBITDA for Q4 2025 rose to 9,524 kEUR, up from 4,306 kEUR in Q4 2024, reflecting improved operational profitability[5][7] - Adjusted EBIT for 2025 increased to 10,601 kEUR from 9,741 kEUR in 2024, with an Adjusted EBIT margin of 4.0%[17] - Gross profit for Q4 2025 was $47.929 million, representing a gross profit margin of 58.1%, up from 55.4% in Q4 2024[34] - Net profit for Q4 2025 was $7.293 million, compared to $2.907 million in Q4 2024, indicating a significant year-over-year increase[35] - Net profit for Q4 2025 was €6,206,000, a significant increase from €2,907,000 in Q4 2024, representing a growth of 114.5%[40] - EBITDA for Q4 2025 reached €8,655,000, up from €4,234,000 in Q4 2024, marking an increase of 104.0%[40] - Adjusted EBITDA for the twelve months ended December 31, 2025, was €32,386,000, compared to €31,484,000 in 2024, reflecting a growth of 2.9%[40] Cash and Financial Position - Cash and cash equivalents at the end of 2025 were 133,918 kEUR, up from 102,304 kEUR at the end of 2024, indicating a strong financial position[15] - Cash and cash equivalents at the end of Q4 2025 were $133.918 million, an increase from $102.304 million at the end of Q4 2024[38] - Total assets as of December 31, 2025, were $420.646 million, compared to $396.336 million as of December 31, 2024[36] - Total equity attributable to the owners of the parent increased to $255.562 million in 2025 from $248.578 million in 2024[37] - The company reported a net cash flow from operating activities of $25.319 million for the twelve months ended December 31, 2025[38] Future Outlook - The company expects full year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR, driven by continued strong growth in the Materialise Medical segment[26][27] - Adjusted EBIT guidance for 2026 is projected to reach between 10,000 to 12,000 kEUR, reflecting ongoing investments and cost control measures[27] Research and Development - Research and development expenses increased by 3.8% to 46,089 kEUR in 2025, primarily due to higher investments in the Materialise Medical segment[21] - Research and development expenses increased to $14.235 million in Q4 2025, up from $12.115 million in Q4 2024[34] - The company plans to continue investing in research and development to enhance its product offerings and market position[32] Operational Expenses - Corporate headquarter costs for Q4 2025 were €3,562,000, an increase from €2,717,000 in Q4 2024, indicating rising operational expenses[45] - The company incurred restructuring costs of €795,000 in Q4 2025, reflecting ongoing corporate initiatives[42] Segment Performance - The Software segment's adjusted EBITDA margin improved to 15.5% in Q4 2025 from 10.1% in Q4 2024[44] - The Manufacturing segment reported a negative adjusted EBITDA of €2,199,000 in Q4 2025, compared to a negative €2,989,000 in Q4 2024, indicating improvement[44] - For the twelve months ended December 31, 2025, the Medical segment's adjusted EBITDA margin was 32.0%, up from 30.6% in 2024[44] Dividend Policy - The company did not pay dividends to equity holders of the parent in 2025[39]